Sinopharm Group Co. Ltd. (hereinafter referred to as Sinopharm Group) announced on 28 November 2025 a series of proposed changes in its board composition and key leadership roles. Non-executive Directors Mr. Zhao and Ms. Feng have resigned, with the effective date contingent upon the appointment of their respective replacements at an upcoming general meeting. Mr. Zhao resigned from his roles as Chairman, authorized representative, and committee member, while Ms. Feng resigned as non-executive Director and committee member. Both indicated no disagreement with the board.
Two non-executive Director candidates, Mr. Jin and Ms. Li, have been nominated, subject to Shareholders’ approval. If approved, Mr. Jin will become the Chairman, the authorized representative, and chair or member of various board committees, overseeing areas such as nominations and strategy. Ms. Li is expected to serve as a non-executive Director with a focus on corporate governance.
To finalize these appointments, Sinopharm Group intends to convene an extraordinary general meeting on 19 December 2025. In preparation, the register of members will be closed from 16 December to 19 December 2025. Shareholders whose names appear on the register starting 16 December will be entitled to attend and vote on these proposals. A detailed circular regarding the proposed appointments will be released according to the company’s usual information dissemination channels.
Comments